Ac-Trp-Leu-Ala-AMC [Ac-WLA-AMC]

CHF 204.00
In stock
SBB-PS0008-M0022 mgCHF 204.00
More Information
Product Details
Synonyms Proteasome Substrate
Product Type Chemical


MW 587.7


CAS 1104011-59-7
Purity Chemicals ≥95% (HPLC)
Appearance Lyophilized powder.
Solubility Soluble in DMSO.
Declaration Manufactured by South Bay Bio.
Other Product Data

Use: After preparing a stock solution in DMSO (≥10mM) store product at -20°C to -80°C. It is recommended to make multiple aliquots after the first thaw to ensure best performance. Chymotrypsin-like activity can be measured using a typical working concentration range from 10-50µM. Click here for a Typical Lot-specific Product Datasheet from the Original Manufacturer
Our product description may differ slightly from the original manufacturers product datasheet.

Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Protect from light.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

Ac-WLA-AMC is a fluorogenic peptid substrate for measuring chymotrypsin-like activity of the proteasome. Hydrolysis of this substrate by the β5-subunit of the 20S proteasome is monitored by observing fluorescence at an Excitation wavelength of 345nm and Emission at 445nm. This substrate is specific to the constitutive proteasome and is not hydrolyzed efficiently by the immunoproteasome. 20S Proteasome enzyme requires activation with 0.035% SDS in the assay buffer.

Product References
  1. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit: C. Blackburn, et al.; Biochem. J. 430, 461 (2010)
  2. The immunoproteasome as a therapeutic target for hematological malignancies: Z. Miller, et al.; Curr. Can. Drug Targets 14, 537 (2014)
  3. Immunoproteasome-selective inhibitors: a promising strategy to treat hematologic malignancies, autoimmune and inflammatory diseases: R. Ettari, et al.; Curr. Med. Chem. 23, 1217 (2016)
  4. Development of Potent and Highly Selective Epoxyketone-based Plasmodium Proteasome Inhibitors: J. Almaliti, et al.; Chemistry ahead of print (2023)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.